IDEAS home Printed from https://ideas.repec.org/h/spr/sprchp/978-981-97-1471-1_3.html
   My bibliography  Save this book chapter

The Golden Age of Chinese Biopharma Sector, 2014–2021: Explosive Growth in a Thriving Ecosystem

In: Biopharma in China

Author

Listed:
  • Sven Agten
  • Ben Wu

Abstract

The Chinese biopharma sector has witnessed an unprecedented growth, referred to as the ‘Golden Age’. A combination of factors has nurtured this explosive domestic growth in the pharma and biotech space. With the largest population in the world and with little access to the latest innovative medicines, China provided huge market opportunities. Regulatory reforms made approval of new drugs much easier, which led to venture capitalists eying the Chinese biopharma sector as new growth sector. The government streamlined the clinical trial and drug approval process, including priority and special reviews as well as breakthrough therapy designations for innovative products that target unmet medical needs in China. The NRDL is also being updated more frequently and prioritizes the entry of newly approved novel drugs. Then there is also the huge number of hospitals which provide a massive set of potential patients to enroll into clinical trials. New capital sources became available, when in 2018 changes in policy allowed pre-revenue/pre-profit biotech companies to be listed in the Hong Kong Stock Exchange (HKEX) or Shanghai Stock Exchange’s Science and Technology Innovative Board (STAR). Combined together, all of these factors can be seen as the rocket booster for growth, which fueled the Golden Age of the Chinese biopharma sector.

Suggested Citation

  • Sven Agten & Ben Wu, 2024. "The Golden Age of Chinese Biopharma Sector, 2014–2021: Explosive Growth in a Thriving Ecosystem," Springer Books, in: Biopharma in China, pages 41-69, Springer.
    • Handle: RePEc:spr:sprchp:978-981-97-1471-1_3
    DOI: 10.1007/978-981-97-1471-1_3
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:sprchp:978-981-97-1471-1_3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.